Dolphin is also designed for future applications, such as Machine QA and Adaptive-QA™ using CBCT and dose of the day. The versatility of Dolphin makes it the universal detector for integrating future real time measurements into IBA’s myQA global QA platform for several key dosimetry applications, from Patient QA to Machine QA and more.
“We are proud to release Dolphin and believe, along with our reference customers, that it’s a milestone solution that will change the way patient QA is done for many years to come,” said Ralf Schira, Vice President Marketing of IBA Dosimetry. “As a first release, we will offer our customers a highly efficient solution for pre-treatment QA.
Ad Statistics
Times Displayed: 45539
Times Visited: 1299 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
However, we are continuing to collaborate with our industry partners to release Dolphin for future online use, specifically, Dolphin with advanced Compass TPS-class software will serve as the basis for future Adaptive QA.
With the introduction of Dolphin and the ability to have it connected to the myQA® global QA platform, as well as gaining full patient QA overview via myQA Cockpit, users will have all QA tools in one place and every patient fraction at their fingertips.”
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba- worldwide.com.
Back to HCB News
